SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-010443
Filing Date
2020-08-12
Accepted
2020-08-12 16:50:41
Documents
67
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20200630x10q.htm 10-Q 1583599
2 EX-31.1 akro-20200630ex31192066c.htm EX-31.1 10337
3 EX-31.2 akro-20200630ex312a4b91e.htm EX-31.2 11245
4 EX-32.1 akro-20200630ex3210d9e2b.htm EX-32.1 10437
  Complete submission text file 0001558370-20-010443.txt   6156053

Data Files

Seq Description Document Type Size
5 EX-101.INS akro-20200630.xml EX-101.INS 1362665
6 EX-101.SCH akro-20200630.xsd EX-101.SCH 42922
7 EX-101.CAL akro-20200630_cal.xml EX-101.CAL 32356
8 EX-101.DEF akro-20200630_def.xml EX-101.DEF 127585
9 EX-101.LAB akro-20200630_lab.xml EX-101.LAB 402885
10 EX-101.PRE akro-20200630_pre.xml EX-101.PRE 299849
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 201095994
SIC: 2834 Pharmaceutical Preparations